Close Menu

NEW YORK (360Dx) — Shares of T2 Biosystems soared today on news that the US Food and Drug Administration granted Breakthrough Device Designation for its T2Resistance Panel.

In morning trading on the Nasdaq, the company's shares were up more than 25 percent at $4.73.

T2 Bio's panel can detect 13 resistance genes from both gram-positive and gram-negative pathogens and from a single patient blood sample without waiting for a blood culture.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Jul
23
Sponsored by
Qiagen

This webinar will discuss how the Molecular Pathology Laboratory at the University of Oklahoma (OUMP) is using a new quality improvement model to support molecular testing of oncology patients. 

Jul
25

This webinar will discuss the evolution of fetal aneuploidy screening and the most recent evidence around the implementation of prenatal cell-free DNA testing in clinical practice.